It is especially a problem after HSCT from unrelated donors because of more profound immunosuppression and more severe. 3, 4 AD-HC is sometimes accompanied by pneumonia, renal infection and viremia resulting in death. 2 Intravenous ribavirin has been reported to be useful in AD-HC. [4] [5] [6] Oral ribavirin has been used for hepatitis C, but its role in adenovirus infections is unclear.
A 41-year-old male with acute lymphoblastic leukemia in first remission received HSCT from an HLA-matched unrelated donor. The preparative regimen consisted of melphalan (180 mg/kg) and total body irradiation (10 Gy). Cyclosporin A (CsA) and short-term methotrexate were administered for the prophylaxis of acute GVHD. Myeloid engraftment (ANC 4500/mm 3 ) occurred on day þ 14 and platelet transfusion independence (count 450000/mm 3 ) was achieved on day þ 37. At 2 weeks after the transplant (day þ 14), he developed grade 2 acute GVHD, which resolved with 1 mg/kg prednisolone. On day þ 50, he suddenly developed painful, gross hematuria with highgrade fever. Adenovirus 11 was isolated from the urine, which was confirmed by polymerase chain reaction (PCR). Real-time quantitative PCR (RQ-PCR) for adenovirus genome performed at day þ 51 showed 7.8 Â 10 6 adenovirus genome per microliter urine (point A in Figure 1 ). Simultaneously, BK virus genome was also tested but resulted in a negative test. Supportive cares such as hydration, diuresis and continuous bladder irrigation failed to control the patient's symptoms. Subsequently, intravenous vidarabine was given at day þ 55; however, clinical symptoms did not improve and adenovirus copies in the urine did not reduce (B). After 4 weeks, there was no clinical improvement and patient's condition was deteriorating. Thus, after informed consent was obtained, oral ribavirin was initiated at day þ 94. The patient received 16 mg/kg orally every 6 h for 4 days, followed by 8 mg/kg every 6 h for 3 days. By day 3 of the treatment, high-grade fever disappeared. The hematuria improved and disappeared after 14 days of treatment. Adenovirus copies of the urine reduced remarkably from 8 Â 10 6 to 10 5 copies/ml urine (C), but still remained positive. After 4 weeks (day þ 130), adenovirus copies again increased to 7.9 Â 10 5 copies/ml (D). After 2 weeks (day þ 144), he presented high-grade fever and macroscopic hematuria again, and adenovirus copies further increased to 5.6 Â 10 6 copies/ml (E). Oral ribavirin 20 mg/kg was started again orally every 6 h for 5 days, followed by 10 mg/kg every 6 h for 4 days. The clinical symptoms improved within 7 days after the therapy, but myelosuppression resulting in neutropenia (grade 3), anemia (grade 2) and thrombocytopenia (National Cancer Institute Common Toxicity Criteria, grade 3) was observed. It lasted for about 2 weeks, regardless of the administration of granulocyte colony stimulating factor (G-CSF). Adenovirus remained positive (around 1 Â 10 4 copies/ml) for more than 14 weeks after the second therapy without the recurrence of clinical manifestations of adenovirus infection (F). Eventually, it turned to an undetectable level at day þ 250 (Figure 1 ) in accordance with the discontinuation of immunosuppressive drugs.
In the current report, oral ribavirin was successfully used in the patient with severe adenovirus infection. Oral ribavirin has been widely used in the treatment of hepatitis C virus infection; however, to the best of our knowledge, this is the first report of oral ribavirin for adenovirus infection. The dose and the duration of oral ribavirin for the treatment of adenovirus infection after HSCT are not established. Initially, we used an equivalent dose of intravenous ribavirin as recommended by NCI pharmaceutical company for Lassa fever. In the second treatment, we used 125% dose of that in the first one. After the second treatment, the myelosuppression was observed. Myelosuppression has been reported in a similar situation. 5 Hemolysis is a well-known adverse effect of ribavirin. 7 However, caution should be taken for the severe myelosuppression by ribavirin after HSCT. It is reported that bioavailability of oral ribavirin is approximately 50%. 8 The appropriate dose may be 200% of the recommended intravenous dose. In the current report, a lower dose of ribavirin was used resulting in the immediate remedy of the disease. The persistent virus in urine may be explained by the low dose of ribavirin, in part; however, myelosuppression developed even with the low dose of ribavirin, suggesting that the full dose of ribavirin may cause severe myelosuppression in the transplant setting.
The efficacy of oral ribavirin is intensively monitored using RQ-PCR, and several findings were obtained. First of all, clinical symptoms occurred exclusively when the virus copy number is more than 100 000, suggesting that a threshold of copy number of adenovirus for clinical manifestation will be defined. Secondly, shortly after the treatment, the number of copies was dramatically reduced according to the improvement of clinical symptoms. The efficacy of oral ribavirin is clearly demonstrated. Thirdly, after the second administration, the copy number of adenovirus sustained for almost 2 months at low level without clinical symptoms. After the cessation of immunosuppression, adenovirus disappeared as shown in the figure. It has been recently reported that failure to reduce immunosuppression is one of the risk factors for developing adenovirus infection. 9 These observations indicate that immunosurveillance system also controls the adenovirus infection.
In conclusion, oral ribavirin is effective in our patient. However, the efficacies of ribavirin remain controversial. [4] [5] [6] 10 Thus, more studies are needed to determine if this antiviral works for AD-HC. University School of Medicine; Sendai, Japan; and
